StockData

Lifevantage vs Ligand Pharmaceuticals

LFVN and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LFVN and LGND compare

Ligand Pharmaceuticals is the larger company, worth 98 times as much as Lifevantage ($5.9B against $59.9M).

On earnings, Lifevantage is cheaper: it trades at 11.9× trailing earnings, against 128× for Ligand Pharmaceuticals.

Ligand Pharmaceuticals grew revenue faster over the last twelve months (1.0% versus −20.1% for Lifevantage).

Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with 2.8% at Lifevantage.

Lifevantage pays a dividend yielding 4.0%; Ligand Pharmaceuticals does not pay one.

Lifevantage scores higher on the StockData Score (20 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLFVNLGND
Size and price
Market cap$59.9M$5.9B
Share price$4.78$293.81
Change, 1 year−27.8%46.3%
Change, 5 years−29.2%87.3%
Beta (5Y)0.590.84
Employees22347
StockData Score
Total score20 (better)6
Valuation score6 (better)0
Growth score11
Performance score4 (better)3
Health score5 (better)2
Dividend score4 (better)0
Valuation
P/E11.9× (better)128×
P/S0.3× (better)23.2×
P/B1.8× (better)6.1×
EV/EBITDA5.1× (better)108×
P/FCF9.0× (better)64.8×
PEG0.46–
FCF yield11.1% (better)1.5%
Fair value$8.48$55.15
Margin of safety43.6% (better)−433%
Growth
Revenue growth (TTM)−20.1%1.0% (better)
Revenue growth, 5Y average−3.7%10.4% (better)
Net income growth (TTM)−48.3%5.9% (better)
EPS growth (TTM)−46.7%18.7% (better)
EPS growth, 5Y average−15.0%–
Profitability
Gross margin77.6%–
Operating margin3.3%10.1% (better)
Net margin2.8%20.3% (better)
FCF margin3.7%35.7% (better)
Return on equity14.9% (better)5.4%
Return on invested capital30.8% (better)2.6%
Financial health
Debt / equity0.001.17 (better)
Net debt / EBITDA–11.26
Interest coverage–3.1×
Current ratio1.89 (better)1.22
Altman Z-score2.543.32 (better)
Piotroski F-score66
Dividends and buybacks
Dividend yield4.0%–
Payout ratio46.2%–
Years of dividend growth1–
Buyback yield3.4%–
Shareholder yield7.4% (better)0.00%
Ownership
Held by institutions47.2%113%
Held by insiders27.8%2.6%
Insider net buying, 12 months$6.0K (better)−$36.5M
Short interest, % of float10.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.